View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 28, 2020updated 07 Sep 2020 1:54pm

Chinese companies contract Generex for Covid-19 vaccine

Four companies in China have entered a contract with Generex Biotechnology for the development of an Ii-Key Peptide-based Covid-19 vaccine.

 

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Four companies in China have entered a contract with Generex Biotechnology for the development of an Ii-Key Peptide-based Covid-19 vaccine.

The Chinese partners comprise China Technology Exchange, Beijing Zhonghua Investment Fund Management, Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development (Shenzhen).

Generex president and CEO Joe Moscato signed a draft contract and will visit China next week to sign the official agreement and finalise work plans.

The vaccine, developed using the company’s Ii-Key immune system activation technology, could be available for human clinical trials within 90 days.

Moscato said: “Our subsidiary NuGenerex Immuno-Oncology has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV and a previous coronavirus, SARS.

“This wealth of experience has enabled us to develop a standardised protocol for rapid vaccine development, so we are positioned to respond in the event of a new, emerging pathogen.

“Our partners in China have recognised the power of our Ii-Key platform and have delivered this contract to establish a collaboration to combat the Covid-19 epidemic, and we are excited to begin the work.”

Under the terms of the contract, the company will receive an upfront payment of $1m to start the Covid-19 vaccine project in the US.

Additional $5m will be received as licensing fee for the Ii-Key technology, along with all costs and expenses associated with the vaccine development and a 20% royalty on each vaccine dose manufactured.

Generex Biotechnology is a combined healthcare holding company, which has end-to-end solutions for patient-centric care from swift analysis through the distribution of personalised treatments.

Generex is constructing an innovative class of healthcare company, extending beyond conventional models offering support to physicians, as well as continuing relationships with patients to enhance the patient experience and access to optimal care.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology